The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy -- and those who won't. The latest trial results extend the test's reach.
Topline data from the Phase II study of tucatinib showed the drug combined with an antibody-chemotherapy combination improved progression-free survival over the doublet by itself. Seattle Genetics acquired the drug when it bought Cascadian for $614 million last year.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
A less invasive treatment for women with small breast cancer tumors could replace standard lumpectomies.